aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
NewLeaf Symbiotics, founded with a mission to revolutionize agriculture through biotechnology, focuses on enhancing plant health and crop yield using beneficial bacteria known as PPFMs (Pink Pigmented Facultative Methylotrophs). The company develops and commercializes these bacteria, which are naturally occurring and promote early growth and increased yield in crops. NewLeaf's products, including the EPA-registered bioinsecticide TS201, are marketed across the United States and aim to integrate seamlessly into existing pest management systems.
Notable figures affiliated with NewLeaf Symbiotics include experienced agricultural scientists and biotech industry veterans. The company has secured investments from prominent venture capital firms, enabling significant research and development advancements. Key achievements include the successful registration of their bioinsecticide with the EPA and the widespread adoption of their products by farmers. NewLeaf Symbiotics has made a substantial impact on sustainable agriculture by providing innovative solutions that enhance crop productivity and resilience.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Crop Protection, Bioinsecticides
Technology
Biotech
Tags
AgTech, Biotech
Model Types
Licensing, Software
Revenue Type(s)
Transactional, Recurring
Customer Type(s)
Enterprise, Agriculture
Geographic Exposure
United States
When was NewLeaf Symbiotics founded?
NewLeaf Symbiotics was founded in 2012.
Where is NewLeaf Symbiotics's headquarters located?
NewLeaf Symbiotics's headquarters is located in St. Louis, MO, US.
When was NewLeaf Symbiotics's last funding round?
NewLeaf Symbiotics's most recent funding round was for $47M (USD) in December 2023.
How many employees does NewLeaf Symbiotics have?
NewLeaf Symbiotics has 45 employees as of Feb 5, 2024.
How much has NewLeaf Symbiotics raised to-date?
As of July 05, 2023, NewLeaf Symbiotics has raised a total of $134.6M (USD) since Dec 19, 2023.
Add Comparison
Total Raised to Date
$134.6M
USD
Last Update Dec 19, 2023
Last Deal Details
$47M
USD
Dec 19, 2023
Series D
Total Employees Over Time
45
As of Feb 2024
NewLeaf Symbiotics Address
1005 North Warson Road
St. Louis,
Missouri
63132
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts